AstraZeneca reports positive data from Phase III mantle cell lymphoma trial

AstraZeneca has reported positive data from the ECHO Phase III clinical trial where its Calquence combination therapy (acalabrutinib) significantly improved progression-free survival (PFS) in patients with untreated MCL.